lk  

www.onirisme.be - SlideShowwww.onirisme.be - SlideShowwww.onirisme.be - SlideShow

Euroscreen

 

read more

R&D Pipeline

 

read more

Management

 

read more

About Us

 

read more

Euroscreen
FAST

 

read more

July 19th, 2016 – Euroscreen announced today that it has opened an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to conduct pivotal efficacy and safety assessments to evaluate ESN364 in Phase II studies for the treatment of menopausal Hot Flashes, Poly Cystic Ovary Syndrome and Uterine Fibroids.

“The opening of these three IND applications is a major milestone for the Company as we progress in the clinical development of ESN364” said Jean Combalbert, CEO of Euroscreen. “Our initial correspondence with the FDA has been very positive and Euroscreen is looking forward to continue working with the agency and other experts to further develop our lead compound in the US. These three INDs, on top of the three clinical studies currently running in Europe, position the company for major future milestones.”

ESN364 is a proprietary, small-molecule NK3 receptor antagonist discovered and developed by Euroscreen, and it is the most advanced product in its target class in clinical development for the treatment of Women’s Health Disorders. The mechanism-of-action of ESN364 offers an advantage over existing therapies for Uterine Fibroids and Endometriosis known to elicit menopause-like adverse events. Moreover, the action of ESN364 to selectively modulate gonadotropins uniquely suits this product for the treatment of Poly Cystic Ovary Syndrome. In addition, ESN364 is a game-changer as the non-hormonal treatment for Hot Flashes, providing an alternative to Hormone Replacement Therapy (HRT).

About Euroscreen

Euroscreen is a Belgium-based, privately owned Drug Discovery Company developing first-in-class small molecule drug candidates targeting G-Protein Coupled Receptors. The Company’s orally-available and highly specific lead product ESN364 is currently in Phase II clinical development for the treatment of Women’s Health Disorders. Euroscreen has other small molecules targeting G-Protein Coupled Receptors in preclinical development in multiple therapeutic areas including CNS, endocrinology and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SRIW, SFPI-FPIM, and Fund+. www.euroscreen.com

Contacts

Ruth Devenyns                                           Al Gray

CFO Director                                              Business Development

+32 71 348 511                                         +1 716 308 6693

This email address is being protected from spambots. You need JavaScript enabled to view it.                 This email address is being protected from spambots. You need JavaScript enabled to view it.

Brussels, Belgium March 4th: Euroscreen today announced the appointment of Mrs. Ruth Devenyns as Chief Financial Officer (CFO).
Ruth Devenyns has a long standing experience in healthcare financing. She began her career with KBC in the Economic Research Department. In 1995 she joined KBC Securities where she established KBC’s investment banking franchise in healthcare, initially as a sell-side analyst and subsequently on the banking side. Around 2000 she moved to the buy-side and successfully built and managed a >EUR 120m portfolio of private biotech companies in Belgium and abroad. In 2012, Ruth left KBC to become an independent consultant, offering investment/financial advisory & director services with a focus on healthcare. In that capacity she worked for Korys, the Colruyt family office, and most recently for Bank Degroof Petercam, supporting the healthcare investment banking activities. Ruth is currently an independent director of Euronext-listed MDxHealth and a board member of FlandersBio, the regional industry organization.
Jean Combalbert, Chief Executive Officer of Euroscreen, commented: “We are delighted that Ruth is joining Euroscreen, she will help us to grow and add shareholder value. Her extensive experience and network in healthcare financing will provide critical support for the advancement of our development pipeline”.
Ruth Devenyns, Chief Financial Officer of Euroscreen, commented: “With several Phase II trials ongoing for the lead product ESN364, an interesting early pipeline and a solid scientific backbone in GPCR-biology, Euroscreen is at a pivotal stage of its development. I look forward to working closely with Jean and the team to ensure the company’s continuing success.”

About Euroscreen

Euroscreen is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs. Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules. Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting G-Protein Coupled Receptors of interest in multiple therapeutic areas such as neurodegenerative diseases and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity. www.euroscreen.com

 

Gosselies, Belgium September 23th 2015 - Euroscreen SA announced today that it has initiated a Phase 2 clinical study for the treatment of menopausal Hot Flashes with ESN364, a new drug for Women’s Health Disorders. The main objective of this clinical trial is to measure the efficacy of ESN364 on the severity and frequency of menopausal Hot Flashes. This double-blind, placebo-controlled, 3-month study is being carried out in 80 symptomatic menopausal women at various clinical sites in Belgium. Hot Flashes are the major medical complaint coincident with menopause. ESN364 has already completed Phase 1 in men and women having demonstrated an excellent safety profile as well as clear drug efficacy on hormone biomarkers. This trial in Hot Flashes is performed in parallel of two ongoing, 3-month, Phase 2 clinical trials evaluating ESN364 for the treatment of Uterine Fibroids (UF) and PolyCystic Ovary Syndrome (PCOS). ESN364 has already demonstrated to be devoid of Hot Flash side effects commonly observed with GnRH therapies. In addition, during preclinical development we demonstrated in animal proof-of-concept studies the ability of ESN364 ability to specifically block the occurrence of Hot Flashes.  “The unique mechanism of action of ESN364 forms the scientific basis of its potential to safely and effectively treat Hot Flashes” said Prof. Herman Depypere (Ghent University), member of the EMAS (European Menopause & Andropause Society), former President of the Belgian Menopause Society, and member of Euroscreen's Clinical Advisory Board. “Encouraged by our recent additional new funds raised, we decided to fund this additional Phase 2 trial; we expect ESN364 to be a game-changer in the treatment of menopausal Hot Flashes, giving us the opportunity to reach this huge and valuable market. The next 12-month period promises to be an exciting time for Euroscreen as ESN364 completes Phase 2 trials in multiple indications” said Jean Combalbert, CEO of Euroscreen.

About Hot Flashes

Hot Flashes are the sudden feelings of intense heat which are usually most intense over the face, neck and chest and can include skin reddening, blushing and profuse sweating. This may occur due to specific drug actions, but are most commonly experienced by 70% of menopausal women. Hormone Replacement Therapy (HRT) approaches have been used to address this medical need, however, HRT approaches are known to increase the incidence of cancer, heart disease and stroke in menopausal women. Thus, there is an important medical need for new, safe therapies.

About ESN364

ESN364 is a proprietary, oral, small-molecule, discovered and developed by Euroscreen for the purpose of the treatment of Women’s Health Disorders. ESN364 is superior to the existing, marketed GnRH ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of UF and Endometriosis. In addition, its selective action on gonadotropins uniquely positions ESN364 for the treatment of PCOS.  Furthermore, its mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of ESN364 to directly and safely address the basis for Hot Flashes in menopausal women.

About Euroscreen

Euroscreen S.A. is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs. Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules. Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting G-Protein Coupled Receptors of interest in multiple therapeutic areas such as neurodegenerative diseases and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SFPI, SRIW, Fund+ and BNP Paribas Fortis Private Equity. Further information about Euroscreen can be found online at www.euroscreen.com

 

Gosselies, Belgium February 10th: Dr. Philippe Monteyne is appointed as partner of Fund+ NV and Dr. Jean-Paul Prieels as an independent non-executive director designated by SFPI.
Philppe Monteyne MD, PhD is VC Partner with Fund+ NV in Belgium, and visiting Professor of Neurosciences at UCL, Catholic University of Louvain in Belgium. From Oct 2012 until end 2014, he was Vice President R&D France, Sanofi, in Paris area, reporting directly to the President Global R&D. Prior to that (2010-2012), Philippe was the Senior Vice President - Head of Development and CMO, GSK Rare Diseases. From 1998 to 2010, he held various executive positions at GlaxoSmithKline, including Head of Global Vaccine Development.
Jean-Paul Prieels PhD is an industry expert in pharmaceutical development. He held various executive positions at GlaxoSmithKline Biologicals where he started in 1987 and has been instrumental in developing several marketed vaccines. He retired from GSK as Senior Vice President Research and Development in early 2011 and is currently a board member of several biotech companies. He is designated by SFPI (Société Fédérale de Participations et d'Investissement, Belgium) to seat on the Board of directors of Euroscreen.
Dr. Monteyne: "At Fund+, we are delighted to join Euroscreen as shareholders and to actively contribute to its success through this role at the Board level. Euroscreen is a highly promising clinical stage company, which fits perfectly with our policy to develop a leadership position in the Life Sciences sector in Belgium."
Dr. Prieels: "I am thrilled to be able to be involved in the development of Euroscreen’s promising pipeline and am grateful to SFPI fort this board membership."
"We are very pleased and proud that Philippe and Jean-Paul have agreed to become members of the Euroscreen Board of Directors. Their proven track record of drug development and accomplishments will bring a lot of experience and expertise in our Board of Directors” commented Jean Combalbert, CEO of Euroscreen.

About Euroscreen

Euroscreen is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs. Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules. Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting G-Protein Coupled Receptors of interest in multiple therapeutic areas such as neurodegenerative diseases and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity. www.euroscreen.com

About SFPI-FPIM

The Federal Holding and Investment Company (SFPI-FPIM) was created on November 1st, 2006 and has the federal government as its sole shareholder. SFPI is focusing its investments on innovative Belgian Companies such as Euroscreen, hoping to contribute to their financial and societal success story. SFPI is also present in the aeronautical, energy and real estate business. www.sfpi-fpim.be

About Fund+ NV

FUND+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. The objective is to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact. www.fundplus.be

 

 

Euroscreen SA, Belgium, November 12, 2014- Euroscreen S.A. announced today that it has entered into an exclusive world-wide research collaboration and licensing agreement with Merck & Co., Inc., through a subsidiary, to discover and further develop compounds active against an undisclosed target for the potential treatment unmet medical needs.

Under the terms of the agreement, Merck, known as MSD outside the United States and Canada, will be responsible for the development of all compounds and products under the collaboration. In exchange, Euroscreen will receive an upfront payment and additional committed undisclosed research funding over the next two to four years.Euroscreen is also eligible to receive certain pre-specified development milestones, which together with upfront payments could amount to over €100 million and royalties on worldwide sales of any future marketed products that may result from the collaboration.
"We are proud to collaborate with Merck to develop new treatments that may address a number of unmet medical needs," said Jean Combalbert, Ph.D., CEO of Euroscreen. “We believe this collaboration further validates our growing drug development capabilities and better positions us to achieve our longer term growth objects.”

Euroscreen S.A. is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including hormonal disorders, inflammation and neurodegenerative diseases.Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules targeting GPCRs.Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health disorders. ESN364 is a proprietary, oral, small molecule discovered and optimized at Euroscreen. This is the first GPCR target antagonist optimized for the purpose of the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting GPCRs of interest for unmet medical needs. Euroscreen is backed by leading investors, including Vesalius Biocapital, SRIW and Fortis Private Equity. Further information about Euroscreen and its drug discovery and development programs can be found online at www.euroscreen.comor by contacting This email address is being protected from spambots. You need JavaScript enabled to view it..

About Euroscreen

Euroscreen has a drug development track-record with multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR).
Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women’s diseases such Endometriosis and PCOS. The Company is also actively seeking partners for other pharmaceutical candidates.
Euroscreen is a Belgium-based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women’s diseases. Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST) for biopharmaceutical companies worldwide.
The Company is backed by leading investors, including Vesalius Biocapital, SRIW, Fortis Private Equity, and others.
Further information about the Company and its drug development programs can be found online at www.euroscreen.com or contacting This email address is being protected from spambots. You need JavaScript enabled to view it..

 

 

Study evaluating ESN364, a novel, non-hormonal small-molecule drug designed to block Hot Flashes avoiding Hormone Replacement Therapy (HRT), known to increase the incidence of cancer in menopausal women.

September 14, 2016 – Euroscreen announced today that it has completed enrollment for its Phase II proof-of-concept clinical study designed to evaluate ESN364, an oral, small molecule NK3 antagonist, for the treatment of Menopausal Hot Flashes.
The double-blind, placebo controlled 12-week study will measure the efficacy of ESN364 in reducing the severity and frequency of Menopausal Hot Flashes in symptomatic menopausal women.The study has enrolled a total of 87 patients at various clinical sites in Belgium and final data are expected by year end 2016.
ESN364 has already successfully completed a Phase I study in men and women demonstrating an excellent safety profile as well as clear drug efficacy on hormone biomarkers. In addition, pre-clinical proof-of-concept studies have shown the ability of ESN364 to specifically block the occurrence of Hot Flashes.
The Phase IIa trial in Menopausal Hot Flashes forms part of a broad program in women’s health, alongside two ongoing Phase IIa clinical trials evaluating ESN364 for the treatment of PolyCystic Ovary Syndrome (PCOS) and Uterine Fibroids (UF). ESN364 has already shown to be devoid of Hot Flash side effects commonly observed with GnRH therapies.
We are encouraged by the interest shown by patients and physicians in this trial as this non-hormonal drug candidate offers an important alternative to estrogen-based drugs presently used to treat severe hot flashes.” said Dr. Steven Ramael, Euroscreen’s Clinical Director.
Jean Combalbert, CEO of Euroscreen said: “There is a clear need for better, non-hormonal treatments for Menopausal Hot Flashes. We look forward to completing this trial and building on the strong data seen so far to support the development of ESN364 in this important indication.”
 

About Hot Flashes 

 

Hot Flashes are the major medical complaint coincident with menopause.Hot Flashes are the sudden feelings of intense heat which are usually most intense over the face, neck and chest and can include skin reddening, blushing and profuse sweating.This may occur due to specific drug actions, but are most commonly experienced by 70% of menopausal women.Hormone Replacement Therapy (HRT) approaches have been used to address this medical need, however, HRT approaches are known to increase the incidence of cancer, heart disease and stroke in menopausal women. Thus, there is an important medical need for new, safe therapies.

 

About ESN364 

 

ESN364 is a proprietary, oral, small-molecule, discovered and developed by Euroscreen for the purpose of the treatment of Women’s Health Disorders. ESN364 is superior to the existing, marketed GnRH ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of UF and Endometriosis. In addition, its selective action on gonadotropins uniquely positions ESN364 for the treatment of PCOS. Furthermore, its mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of ESN364 to directly and safely address the basis for Hot Flashes in menopausal women.

 

About Euroscreen

 

Euroscreen is a Belgium-based, privately owned Drug Discovery Company developing first-in-class small molecule drug candidates targeting G-Protein Coupled Receptors (GPCRs). The Company’s orally-available and highly specific lead product ESN364 is currently in Phase II clinical development for the treatment of Women’s Health Disorders. Euroscreen has other small molecules targeting GPCRs in preclinical development in multiple therapeutic areas including CNS, endocrinology and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SRIW, SFPI-FPIM, and Fund+.

 

Gosselies, Belgium, June 17, 2013 /PRNewswire/ - Euroscreen SA presented ESN314, a potent small-molecule NK3 receptor antagonist, at the Endocrine Society’s Annual Meeting in San Francisco. Euroscreen and collaborating scientists disclosed preclinical pharmacokinetic and efficacy data demonstrating the utility of NK3 antagonists to modulate the Hypothalamic-Pituitary-Gonadal (HPG) axis, a validated therapeutic axis targeted for the treatment of sex hormone disorders.

This study provides the first demonstration that the oral administration of ESN314 decreases the plasma levels of Lutenizing Hormone (LH), but not Follicle-Stimulating Hormone (FSH) in non-rodent models. This selective reduction of plasma LH offers a more refined modulation of the HPG axis than the existing GnRH antagonist therapies.

ESN314 is a representative molecule from the proprietary series discovered at Euroscreen. The lead development candidate issued from this program, ESN364, is on-schedule for first-in-human dosing in Q4, 2013. Euroscreen will develop its lead candidate ESN364 for the treatment of reproductive disorders such as Endometriosis and Polycystic Ovary Syndrome (PCOS).

"Hormone disorder diseases such as Endometriosis, PCOS or Benign Prostate Hyperplasia (BPH) represent a huge market opportunity with a persistent medical need for new products with a superior profile to the existing therapies” said Jean Combalbert, CEO of Euroscreen. “We are the leaders in drug development for this first-in-class approach. Our drug candidate has an excellent preclinical safety and efficacy profile and we look forward to the outcomes of the Clinical Phase I studies in the coming months.”

About Euroscreen

Euroscreen has a drug development track-record with multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR). Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women’s diseases such Endometriosis and PCOS. The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis. Euroscreen is a Belgium-based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women’s diseases. Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST) for biopharmaceutical companies worldwide. The Company is backed by leading investors, including Vesalius Biocapital, SRIW, Fortis Private Equity, and others.
Further information about the Company and its drug development programs can be found online at www.euroscreen.com or contacting  This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Euroscreen SA, Brussels, Belgium, October 2, 2015 – Euroscreen a drug development company announces today that they have completed a €16 million Series B fundraising round. An existing shareholder, Pierre Drion, brought SFPI-FPIM as a new investor which together with Fund+ co-led this new investment round. The existing shareholders including Vesalius Biocapital II Partners, SRIW SA, BNP Paribas Fortis Private Equity, and another new comer as Capricorn Health-Tech Fund NV are also participating. Euroscreen’s ESN364 advanced drug candidate is progressing with very promising expectations in the treatment of menopausal Hot Flashes and other Women’s Health Disorders such as, PolyCystic ovary syndrome (PCOS), Uterine Fibroids (UF) and Endometriosis.

Funds will be used by Euroscreen to extend ESN364 development:

-    (i) filing an IND in US;

-    (ii) preforming long term toxicology studies to support future clinical chronic treatment; and

-    (iii) supporting the ongoing Phase II clinical trials vs. menopausal Hot Flashes, PCOS and UF.

Jean Combalbert, CEO,commenting on today’s announcement, said: “Euroscreen’s ability to attract funding as we raised over 28M€ (12M€ raised end 2012) over the past 3 years, positions us in the top European healthcare biotech fundraising operations carried out during this period of time. ESN364 development going forward, together with our past and ongoing pharma collaborations have validated the quality and performance of our drug discovery and development track-record. With our current cash resources, we are now well positioned to execute our plans and deliver significant stakeholder value over the next 18-months”. Koen van Loo, Managing Director at SFPI-FPIM said: ”Euroscreen has made tremendous and promising progress since three years. We are very pleased to join the strong syndicate by investing in this Series B round and are convinced of the added value Euroscreen will deliver in the coming years”. Chris Buyse, Managing Partner at Fund+ NV added "Euroscreen is one of the companies that we put in our top-list of investments when we recently created our fund, and we really expect Euroscreen's ESN364 will be the first true therapeutic available for both Hot Flashes and PCOS. We are also excited about Euroscreen's pipeline, and commit to help Euroscreen based on the expertise of our team, with our objective to invest smart money.”

About ESN364

ESN364 is a proprietary, oral, small-molecule, discovered and developed by Euroscreen for the purpose of the treatment of Women’s Health Disorders. ESN364 is superior to the existing, marketed GnRH ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of UF and Endometriosis. In addition, its selective action on gonadotropins uniquely positions ESN364 for the treatment of PCOS. Furthermore, its mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of ESN364 to directly and safely address the basis for Hot Flashes in menopausal women.

About Euroscreen

Euroscreen S.A. is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs. Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules. Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting G-Protein Coupled Receptors of interest in multiple therapeutic areas such as neurodegenerative diseases and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity. Further information about Euroscreen can be found online at www.euroscreen.com

About SFPI-FPIM

The Federal Holding and Investment Company (SFPI-FPIM) was created on November 1st, 2006 and has the federal government as its sole shareholder. SFPI is focusing its investments on innovative Belgian Companies such as Euroscreen, hoping to contribute to their financial and societal success story. SFPI is also present in the aeronautical, energy and real estate business.

About Fund+ NV

FUND+ is a long term investor in innovative companies in Life Sciences in order to create sustainable shareholders value and contribute to the development and anchorage of these companies in Belgium. The fund has the intention to generate a measurable, beneficial social impact alongside a financial return. The fund is incorporated for an unlimited duration.

 

 

Worldwide Renowned Clinicians to Guide ESN364 Promising Developments

Euroscreen SA, Gosselies, Belgium,June 24th, 2013 –Euroscreen, a drug development company focused on the development of novel GPCR drug concepts announced its Clinical Advisory Board members as experts in therapy and disease management in the field of Women’s Health Disorders.Philippe Bouchard, M.D., Professor of Medicine, specialized in Endocrinology, Obstetrics and Gynecology from Pierre et Marie Curie University in Paris, France; Bart Fauser, M.D., Ph.D., Professor of Reproductive Medicine from University of Utrecht, The Netherlands; Richard Legro, M.D., Professor of Obstetrics and Gynecology at Penn State Clinical and Translational Institute, Pennsylvania, USA; and Hugh Taylor, M.D., Professor of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine, Connecticut, USA.

“We are proud to have assembled such a Board of world experts in Women’s Health. The insight and guidance provided by our Clinical Advisors is a major asset in promoting the successful development of our first-in-class drug candidate, ESN364,” said Jean Combalbert, CEO of Euroscreen. “ESN364 is on-schedule for initiation of Phase I studies in Q3, 2013 and Phase II proof-of-concept studies are projected to begin in Q4, 2014”.

Philippe Bouchard, M.D., is presently Professor of Medicine and the Head of Endocrinology and Director of EA 1533, Genetics of Human Reproduction at Hospital St Antoine, Paris, France. He is internationally known within the fields of Endocrinology, Reproduction, Diabetology, and Nutrition, and he is the Past President of the Société Française d'Endocrinologie (SFE). Prof. Bouchard serves the European Society of Gynecology (ESG) as their Honorary Chairman, and he is also a member and the Secretary of the Executive Committee of the European Society of Endocrinology (ESE). Since 1989 he has been a member of the International Committee for Contraception Research (ICCR); a network of scientists and clinical investigators who conduct clinical trials to test the safety, efficacy, and acceptability of Council-developed reproductive health products. In 2002 he was received as a doctor Honoris Causa by the University of Liège, Belgium. In 2008 he was elected as corresponding member of the National Academy of Medicine (2008).

Bart CJM Fauser, M.D., Ph.D.is Professor of Reproductive Medicine, University of Utrecht, The Netherlands. Chair Division of Woman & Baby (Dpts Reproductive Medicine & Gynecology, Obstetrics, Neonatology), University Medical Center, Utrecht, (since 2004). Former Professor of Reproductive Endocrinology and director Center of Reproductive Medicine, Erasmus Medical Center, Rotterdam, The Netherlands (1996-2003); Visiting Professor, University Southampton, UK (since 2010), Saal van Zwanenberg Professor, Center of Reproductive Medicine, Free University, Brussels, Belgium (2003-2008); Visiting Professor, Stanford School of Medicine, Palo Alto, California, USA (1993-1995), and Fulbright post-doctoral Scholar, University of California, San Diego, California (1987-1988). Former Editor-in-Chief ‘Human Reproduction Update’ (2001-2007). His major research interest is the pathophysiology of human ovarian function. He serves on many international editorial boards, has been active in many international societies.

Richard S Legro, M.D.is Professor of Obstetrics and Gynecology and Public Health Sciences and Co-Leader, Clinical Services Core (CSC) of the Penn State Clinical and Translational Institute. His research and clinical practice are primarily focused on polycystic ovary syndrome (PCOS), but he has extensive experience in infertility studies (male and female), leiomyomas, studies of reproductive maturation, and noncontraceptive indications for hormonal contraception, including the treatment of female hirsutism and dysmenorrhea.He has served as the lead principal investigator on many multicenter randomized controlled trials in these areas. He is an Associate Editor of Fertility and Sterility and Seminars of Reproductive Medicine and on the editorial board of Endocrine Reviews and Endocrinology. He has been active in many professional organizations in Endocrinology and Reproductive Medicine.

Hugh Taylor, M.D.is the Anita O'Keeffe Young Professor and Chair, Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics and Gynecology at Yale-New Haven Hospital. He is also Professor of Molecular, Cellular and Developmental biology at Yale University. His clinical interests include IVF, infertility, endometriosis, implantation, menopause, uterine anomalies and DES exposure. He is a board certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. His clinical research centers on implantation, endometriosis and menopause. His basic science research focuses on uterine development, the regulation of developmental gene expression by sex steroids, endocrine disruption, and on stem cells. He is the Editor-In-Chief of Reproductive Sciences.

About Euroscreen

Euroscreen has a drug development track-record with multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR).
Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women’s diseases such Endometriosis and Poly-Cystic Ovary Syndrome (PCOS).The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis. Euroscreen is a Belgium based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women’s diseases. Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST) for biopharmaceutical companies worldwide. The Company is backed by leading investors, including Vesalius Biocapital, SRIW, Fortis Private Equity, and others. Further information about the Company and its drug development programs can be found online at www.euroscreen.com or contacting This email address is being protected from spambots. You need JavaScript enabled to view it..

 


                     Contact

contact us OK

euroscreen final

Euroscreen SA 47 Rue Adrienne Bolland, 6041 Gosselies, Belgium   Tel: +32 71 348 500
Fax: +32 71 348 519
This email address is being protected from spambots. You need JavaScript enabled to view it.
Europe Wallonie

Copyright © 2015 Euroscreen S.A.

Template Joomla créé par onirisme.be